Looking at the filing, I need to extract the key financial details. The filing appears to be truncated - it cuts off in the forward-looking statements section before reaching the financial statements. Let me work with what is available.

Edgewise Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 4, 2026, disclosing operational and financial information for the third quarter of fiscal year 2026.

Key Highlights

  • Shares outstanding: As of October 31, 2026, the company reported 109,482,763 shares of common stock outstanding.
  • Filer classification: The company indicated it is classified as a large accelerated filer, not a smaller reporting company or emerging growth company.
  • Exchange listing: Common stock, par value $0.0001 per share, is listed on the Nasdaq Global Select Market under the ticker EWTX (NASDAQ:EWTX).
  • Principal address: The registrant's principal executive offices are located at 1715 38th St., Boulder, CO 80301.
  • Key pipeline programs: According to the filing, the company's disclosed product candidates include EDG-7500, EDG-15400, and product candidates from its EDG-003 cardiometabolic discovery program.
  • Filing compliance: The registrant confirmed it has filed all required reports during the preceding 12 months and has been subject to filing requirements for the past 90 days.

Edgewise Therapeutics Discloses Pipeline Focus and Share Count in Q3 2026 Report

Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a Delaware-incorporated biopharmaceutical company headquartered in Boulder, Colorado, submitted its Form 10-Q for the quarterly period ended September 30, 2026. The filing carries Commission File Number 001-40236 and reports 109,482,763 shares of common stock outstanding as of October 31, 2026, according to the cover page disclosure.

The company described its focus as cardiovascular and cardiometabolic diseases, citing what it called "our proprietary drug discovery platform" as the basis for developing its pipeline. The filing identifies EDG-7500 as the primary priority, stating the company plans "to focus the majority of our resources on the development of EDG-7500." Additional disclosed programs include EDG-15400 and candidates from the EDG-003 cardiometabolic discovery program. The company noted its continued reliance on third parties for preclinical studies, clinical trials, and manufacturing of its product candidates.

The filing's forward-looking statements section, which the company characterized as subject to risks and uncertainties, addressed topics including the timing and results of clinical trials, regulatory filings with the FDA, potential Investigational New Drug (IND) applications, commercialization planning, and intellectual property positions. The company noted forward-looking statements may be identified by terms such as "may," "will," "could," "would," "should," and comparable terminology. These statements are the company's own and are subject to its cautionary language as described in the filing.

What Was Disclosed

Edgewise Therapeutics filed its Form 10-Q for Q3 2026, reporting 109,482,763 shares outstanding as of October 31, 2026. The company identified EDG-7500, EDG-15400, and EDG-003 program candidates as its primary pipeline, with EDG-7500 described as the top resource priority.